247 related articles for article (PubMed ID: 17006886)
1. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
van Laarhoven HW; Klomp DW; Rijpkema M; Kamm YL; Wagener DJ; Barentsz JO; Punt CJ; Heerschap A
NMR Biomed; 2007 Apr; 20(2):128-40. PubMed ID: 17006886
[TBL] [Abstract][Full Text] [Related]
2. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
3. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases.
van Laarhoven HW; Rijpkema M; Punt CJ; Ruers TJ; Hendriks JC; Barentsz JO; Heerschap A
J Magn Reson Imaging; 2003 Sep; 18(3):315-20. PubMed ID: 12938126
[TBL] [Abstract][Full Text] [Related]
4. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer.
Zahra MA; Tan LT; Priest AN; Graves MJ; Arends M; Crawford RA; Brenton JD; Lomas DJ; Sala E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):766-73. PubMed ID: 19019563
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
[TBL] [Abstract][Full Text] [Related]
6. Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas.
Toms AP; White LM; Kandel R; Bleakney RR; Noseworthy M; Lee S; Blackstein ME; Wunder J
Acta Radiol; 2009 Jun; 50(5):512-20. PubMed ID: 19431058
[TBL] [Abstract][Full Text] [Related]
7. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET.
van Laarhoven HW; de Geus-Oei LF; Wiering B; Lok J; Rijpkema M; Kaanders JH; Krabbe PF; Ruers T; Punt CJ; van der Kogel AJ; Oyen WJ; Heerschap A
Radiology; 2005 Oct; 237(1):181-8. PubMed ID: 16183932
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate.
Vriens D; van Laarhoven HW; van Asten JJ; Krabbe PF; Visser EP; Heerschap A; Punt CJ; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2009 Nov; 50(11):1777-84. PubMed ID: 19837750
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy of liver metastases. Comparison of target volumes and dose-volume histograms employing CT- or MRI-based treatment planning.
Pech M; Mohnike K; Wieners G; Bialek E; Dudeck O; Seidensticker M; Peters N; Wust P; Gademann G; Ricke J
Strahlenther Onkol; 2008 May; 184(5):256-61. PubMed ID: 18427756
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis.
Walker-Samuel S; Leach MO; Collins DJ
Phys Med Biol; 2006 Jul; 51(14):3593-602. PubMed ID: 16825751
[TBL] [Abstract][Full Text] [Related]
13. [Quantitative dynamic MRI and localisation of non-palpable prostate cancer].
Cornud F; Beuvon F; Thévenin F; Chauveinc L; Vieillefond A; Descazeaux A; Flam T
Prog Urol; 2009 Jun; 19(6):401-13. PubMed ID: 19467459
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer.
Del Freo A; Fiorentini G; Sanguinetti F; Muttini MP; Pennucci C; Mambrini A; Pacetti P; Della Seta R; Lombardi M; Torri T; Cantore M
In Vivo; 2006; 20(6A):743-6. PubMed ID: 17203759
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study.
Oto A; Fan X; Mustafi D; Jansen SA; Karczmar GS; Rubin DT; Kayhan A
Acad Radiol; 2009 Oct; 16(10):1223-30. PubMed ID: 19524458
[TBL] [Abstract][Full Text] [Related]
17. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI.
Johansen R; Jensen LR; Rydland J; Goa PE; Kvistad KA; Bathen TF; Axelson DE; Lundgren S; Gribbestad IS
J Magn Reson Imaging; 2009 Jun; 29(6):1300-7. PubMed ID: 19472387
[TBL] [Abstract][Full Text] [Related]
18. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
Mendichovszky IA; Cutajar M; Gordon I
Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
[TBL] [Abstract][Full Text] [Related]
20. Vasopressin selectively increases 5-fluorouracil uptake by colorectal liver metastases following hepatic artery bolus infusion.
Dietz DW; Casillas S; Jones SC; Milsom JW
J Surg Res; 1998 Jul; 77(2):150-6. PubMed ID: 9733602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]